​

Acutus Medical (AFIB) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

AFIB Stock Forecast

Acutus Medical stock forecast is as follows: an average price target of $1.50 (represents a 2784.62% upside from AFIB’s last price of $0.05) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

AFIB Price Target

The average price target for Acutus Medical (AFIB) is $1.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential 2784.62% upside from AFIB's last price of $0.05.

AFIB Analyst Ratings

Buy

According to 1 Wall Street analysts, Acutus Medical's rating consensus is 'Buy'. The analyst rating breakdown for AFIB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Acutus Medical Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 24, 2022BTIG$1.50$0.57165.39%2784.62%

The latest Acutus Medical stock forecast, released on Jun 24, 2022 by BTIG company, set a price target of $1.50, which represents a 165.39% increase from the stock price at the time of the forecast ($0.57), and a 2784.62% increase from AFIB last price ($0.05).

Acutus Medical Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.05$0.05$0.05
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Acutus Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Acutus Medical's last price of $0.05. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jun 24, 2022BTIGBuyBuyHold

Acutus Medical's last stock rating was published by BTIG on Jun 24, 2022. The company gave AFIB a "Buy" rating, the same as its previous rate.

Acutus Medical Financial Forecast

Acutus Medical Revenue Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22
Revenue-----------$4.17M$4.96M--
Avg Forecast$12.40M$10.90M$10.00M$9.00M$8.67M$7.76M$7.59M$6.24M$6.34M$4.81M$4.49M$3.86M$4.44M$3.67M$3.84M
High Forecast$12.40M$10.90M$10.00M$9.00M$8.67M$7.76M$7.59M$6.24M$6.34M$4.81M$4.49M$3.86M$4.44M$3.67M$3.84M
Low Forecast$12.40M$10.90M$10.00M$9.00M$8.67M$7.76M$7.59M$6.24M$6.34M$4.81M$4.49M$3.86M$4.44M$3.67M$3.84M
# Analysts-------111-----
Surprise %-----------1.08%1.12%--

Acutus Medical's average Quarter revenue forecast for Jul 23 based on 0 analysts is $4.49M, with a low forecast of $4.49M, and a high forecast of $4.49M. AFIB's average Quarter revenue forecast represents a 7.70% increase compared to the company's last Quarter revenue of $4.17M (Mar 23).

Acutus Medical EBITDA Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22
# Analysts-------111-----
EBITDA-----------$-15.94M$-18.50M--
Avg Forecast$-12.40M$-10.90M$-10.00M$-9.00M$-8.67M$-7.76M$-7.59M$-6.24M$-6.34M$-4.81M$-4.49M$-3.86M$-4.44M$-3.67M$-3.84M
High Forecast$-12.40M$-10.90M$-10.00M$-9.00M$-8.67M$-7.76M$-7.59M$-6.24M$-6.34M$-4.81M$-4.49M$-3.86M$-4.44M$-3.67M$-3.84M
Low Forecast$-12.40M$-10.90M$-10.00M$-9.00M$-8.67M$-7.76M$-7.59M$-6.24M$-6.34M$-4.81M$-4.49M$-3.86M$-4.44M$-3.67M$-3.84M
Surprise %-----------4.13%4.17%--

undefined analysts predict AFIB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acutus Medical's previous annual EBITDA (undefined) of $NaN.

Acutus Medical Net Income Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22
# Analysts-------111-----
Net Income-----------$-16.63M$15.11M--
Avg Forecast$-5.64M$-5.94M$-6.24M$-6.24M$-11.94M$-12.16M$-11.13M$-11.11M$-11.69M$-18.43M$-18.38M$-19.81M$-20.29M$-23.34M$-23.66M
High Forecast$-5.64M$-5.94M$-6.24M$-6.24M$-11.94M$-12.16M$-11.13M$-11.11M$-11.69M$-18.43M$-18.38M$-19.81M$-20.29M$-23.34M$-23.66M
Low Forecast$-5.64M$-5.94M$-6.24M$-6.24M$-11.94M$-12.16M$-11.13M$-11.11M$-11.69M$-18.43M$-18.38M$-19.81M$-20.29M$-23.34M$-23.66M
Surprise %-----------0.84%-0.74%--

Acutus Medical's average Quarter net income forecast for Mar 23 is $-19.81M, with a range of $-19.81M to $-19.81M. AFIB's average Quarter net income forecast represents a -231.10% decrease compared to the company's last Quarter net income of $15.11M (Dec 22).

Acutus Medical SG&A Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22
# Analysts-------111-----
SG&A-----------$9.56M$9.45M--
Avg Forecast$57.26M$50.33M$46.18M$41.56M$40.05M$35.84M$35.07M$28.83M$29.29M$22.20M$20.74M$17.81M$20.51M$16.93M$17.72M
High Forecast$57.26M$50.33M$46.18M$41.56M$40.05M$35.84M$35.07M$28.83M$29.29M$22.20M$20.74M$17.81M$20.51M$16.93M$17.72M
Low Forecast$57.26M$50.33M$46.18M$41.56M$40.05M$35.84M$35.07M$28.83M$29.29M$22.20M$20.74M$17.81M$20.51M$16.93M$17.72M
Surprise %-----------0.54%0.46%--

Acutus Medical's average Quarter SG&A projection for Jul 23 is $20.74M, based on 0 Wall Street analysts, with a range of $20.74M to $20.74M. The forecast indicates a 116.81% rise compared to AFIB last annual SG&A of $9.56M (Mar 23).

Acutus Medical EPS Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22
# Analysts-------111-----
EPS-----------$-0.58$0.53--
Avg Forecast$-0.19$-0.20$-0.21$-0.21$-0.40$-0.41$-0.37$-0.37$-0.39$-0.62$-0.62$-0.67$-0.68$-0.79$-0.80
High Forecast$-0.19$-0.20$-0.21$-0.21$-0.40$-0.41$-0.37$-0.37$-0.39$-0.62$-0.62$-0.67$-0.68$-0.79$-0.80
Low Forecast$-0.19$-0.20$-0.21$-0.21$-0.40$-0.41$-0.37$-0.37$-0.39$-0.62$-0.62$-0.67$-0.68$-0.79$-0.80
Surprise %-----------0.87%-0.78%--

According to 0 Wall Street analysts, Acutus Medical's projected average Quarter EPS for Mar 23 is $-0.67, with a low estimate of $-0.67 and a high estimate of $-0.67. This represents a -225.85% decrease compared to AFIB previous annual EPS of $0.53 (Dec 22).

Acutus Medical Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
DCTHDelcath Systems$11.34$22.0094.00%Buy
ATECAlphatec$9.23$16.6079.85%Buy
OFIXOrthofix Medical$17.34$24.0038.41%
NPCENeuroPace$11.14$15.0034.65%Buy
CVRXCVRx$12.90$14.2510.47%Buy
AORTArtivion$28.55$30.757.71%Buy

AFIB Forecast FAQ

Is Acutus Medical a good buy?

Yes, according to 1 Wall Street analysts, Acutus Medical (AFIB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of AFIB's total ratings.

What is AFIB's price target?

Acutus Medical (AFIB) average price target is $1.5 with a range of $1.5 to $1.5, implying a 2784.62% from its last price of $0.052. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Acutus Medical stock go up soon?

According to Wall Street analysts' prediction for AFIB stock, the company can go up by 2784.62% (from the last price of $0.052 to the average price target of $1.5), up by 2784.62% based on the highest stock price target, and up by 2784.62% based on the lowest stock price target.

Can Acutus Medical stock reach $0?

AFIB's average twelve months analyst stock price target of $1.5 supports the claim that Acutus Medical can reach $0 in the near future.

What are Acutus Medical's analysts' financial forecasts?

Acutus Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.27M (high $30.27M, low $30.27M), average EBITDA is $-30.27M (high $-30.27M, low $-30.27M), average net income is $-46.337M (high $-46.337M, low $-46.337M), average SG&A $139.78M (high $139.78M, low $139.78M), and average EPS is $-1.561 (high $-1.561, low $-1.561). AFIB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $42.3M (high $42.3M, low $42.3M), average EBITDA is $-42.3M (high $-42.3M, low $-42.3M), average net income is $-24.052M (high $-24.052M, low $-24.052M), average SG&A $195.33M (high $195.33M, low $195.33M), and average EPS is $-0.81 (high $-0.81, low $-0.81).

Did the AFIB's actual financial results beat the analysts' financial forecasts?

Based on Acutus Medical's last annual report (Dec 2023), the company's revenue was $3.03M, which missed the average analysts forecast of $19.5M by -84.45%. Apple's EBITDA was $41.04M, missing the average prediction of $-19.498M by -310.50%. The company's net income was $28.83M, missing the average estimation of $-68.303M by -142.21%. Apple's SG&A was $20.32M, missing the average forecast of $90.04M by -77.44%. Lastly, the company's EPS was $-1.4, missing the average prediction of $-2.3 by -39.14%. In terms of the last quarterly report (Mar 2023), Acutus Medical's revenue was $4.17M, beating the average analysts' forecast of $3.86M by 8.13%. The company's EBITDA was $-15.938M, beating the average prediction of $-3.856M by 313.28%. Acutus Medical's net income was $-16.63M, missing the average estimation of $-19.806M by -16.03%. The company's SG&A was $9.56M, missing the average forecast of $17.81M by -46.29%. Lastly, the company's EPS was $-0.58, missing the average prediction of $-0.667 by -13.04%